The costs of depression : Direct and indirect ; treatment versus nontreatment.
Symposium "Depression and Anxiety : New Tools for Diagnosis and Treatment". Chicago, IL, USA, 1997/08/15.
Depression is one of the most costly illnesses in the United States today.
While managed care often focuses on the costs of treatment, the costs of nontreatment are usually ignored.
We have potent treatments that are highly successful, but depression is often undetected or undertreated where it appears most commonly : in the primary care setting.
When comorbid with other medical problems, especially cardiovascular disease, depression greatly increases mortality, morbidity, and expense.
Sophisticated pharmacoeconomic analyses can guide our cost/benefit studies, but the real cost savings and highest quality care will come by investing in educating primary care physicians regarding the recognition and treatment of psychiatric illness as it presents in their clinical practices.
Mots-clés Pascal : Etat dépressif, Analyse coût, Système santé, Etats Unis, Amérique du Nord, Amérique, Soin santé primaire, Economie santé, Santé mentale, Traitement, Homme, Trouble humeur
Mots-clés Pascal anglais : Depression, Cost analysis, Health system, United States, North America, America, Primary health care, Health economy, Mental health, Treatment, Human, Mood disorder
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0091914
Code Inist : 002B18H05B. Création : 31/05/1999.